16187086

Source:http://linkedlifedata.com/resource/pubmed/id/16187086

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0003250, umls-concept:C0009429, umls-concept:C0021756, umls-concept:C0025202, umls-concept:C0030705, umls-concept:C0279226, umls-concept:C0281581, umls-concept:C0920321, umls-concept:C1261473
pubmed:issue	7
pubmed:dateCreated	2006-3-28
pubmed:abstractText	We conducted a phase I trial of interleukin 2 (IL-2) in combination with chimeric 14.18 (ch14.18) and murine R24 antibodies to determine the maximal tolerated dose (MTD), immunological effects, and toxicity of this treatment combination.
pubmed:grant	http://linkedlifedata.com/resource/pubmed/grant/M01-RR03186, http://linkedlifedata.com/resource/pubmed/grant/P30-CA14520, http://linkedlifedata.com/resource/pubmed/grant/R01-CA32685
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/8605732
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Anti-Idiotypic, http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, http://linkedlifedata.com/resource/pubmed/chemical/Immunologic Factors, http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-2, http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins, http://linkedlifedata.com/resource/pubmed/chemical/ch14.18 monoclonal antibody
pubmed:status	MEDLINE
pubmed:month	Jul
pubmed:issn	0340-7004
pubmed:author	pubmed-author:AlbertiniMark RMR, pubmed-author:ChoiBrian SBS, pubmed-author:GanJacekJ, pubmed-author:HankJacquelyn AJA, pubmed-author:KendraKariK, pubmed-author:KimKyungmannK, pubmed-author:KingDavid MDM, pubmed-author:LeeLi-YinLY, pubmed-author:MahviDavidD, pubmed-author:SchalchHeidiH, pubmed-author:SondelPaul MPM
pubmed:issnType	Print
pubmed:volume	55
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	761-74
pubmed:dateRevised	2011-7-29
pubmed:meshHeading	pubmed-meshheading:16187086-Adult, pubmed-meshheading:16187086-Angioedema, pubmed-meshheading:16187086-Antibodies, Anti-Idiotypic, pubmed-meshheading:16187086-Antibodies, Monoclonal, pubmed-meshheading:16187086-Antibody-Dependent Cell Cytotoxicity, pubmed-meshheading:16187086-Combined Modality Therapy, pubmed-meshheading:16187086-Dose-Response Relationship, Immunologic, pubmed-meshheading:16187086-Drug Administration Schedule, pubmed-meshheading:16187086-Female, pubmed-meshheading:16187086-Humans, pubmed-meshheading:16187086-Immunologic Factors, pubmed-meshheading:16187086-Immunotherapy, pubmed-meshheading:16187086-Interleukin-2, pubmed-meshheading:16187086-Killer Cells, Lymphokine-Activated, pubmed-meshheading:16187086-Lymphocyte Subsets, pubmed-meshheading:16187086-Male, pubmed-meshheading:16187086-Melanoma, pubmed-meshheading:16187086-Middle Aged, pubmed-meshheading:16187086-Recombinant Proteins, pubmed-meshheading:16187086-Salvage Therapy, pubmed-meshheading:16187086-Sarcoma, pubmed-meshheading:16187086-Treatment Outcome
pubmed:year	2006
pubmed:articleTitle	Phase I trial of combined treatment with ch14.18 and R24 monoclonal antibodies and interleukin-2 for patients with melanoma or sarcoma.
pubmed:affiliation	Department of Medicine, University of Wisconsin, Madison, 53792, USA.
pubmed:publicationType	Journal Article, Multicenter Study, Clinical Trial, Phase I, Research Support, N.I.H., Extramural